Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712603 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
Send to Friend
Enquire before Buying
Electronic  Add to Basket
Hard Copy  Add to Basket
Online Access  Add to Basket



Novartis: Performance - Products - Pipeline - Potential
Espicom Business Intelligence Ltd, Nov 2009, Pages: 268


  Description  
  Table of Contents  
  Summary  
  Companies Mentioned  
    
   
 Enquire before Buying  
 Send to a Friend  

Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. Novartis is currently organised into the four divisions of Pharmaceuticals, Consumer Health, Sandoz, and Vaccines & Diagnostics, created following the acquisition of Chiron Corporation. Within Pharmaceuticals, the company's current growth drivers include Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate).

Novartis delivered a steady performance in 2008. Operating income was down by 30.1 per cent and net income down by 31.2 per cent. Within Pharmaceuticals, Novartis' strategic products such as Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate) continued to perform well, while Consumer Health benefited from the North American OTC business of Bristol-Myers Squibb which was acquired in 2005. Sales at Sandoz increased by 20.3 per cent due to the continued effects of the Hexal and Eon Labs acquisitions, which have made it a world leader in generics.

In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 139 compounds under development. With a number of projects in late-stage development, of particular note is fingolimod, which is under Phase III development for multiple sclerosis.

This new strategic analysis report Novartis: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.



Customers who bought this item also bought

Incontinence Products in the United States

Dainippon Sumitomo: Performance, Products, Pipeline and Potential

Roche - Pipeline - Products - Performance - Potential

PharmaVitae 2004: Roche Global and US Analysis

Bayer: Performance, Products, Pipeline and Potential

Chinese Markets for Laundry Care Products

Shionogi: Performance, Products, Pipeline and Potential

sanofi-aventis - Pipeline - Products - Performance - Potential



Top of page


   All rights reserved. ? Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds